$TJX

MEYROWITZ CAROL sold $9.1M of TJX

MEYROWITZ CAROL (Executive Chairman) sold 55,624 shares of TJX COMPANIES INC /DE/ (TJX) at $163.65 ($9.10M total) on 2026-06-09.

Original reporting
SEC EDGAR · MEYROWITZ CAROL
Published Jun 10, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TJX
Neutral
medium confidence
Mentioned
$TJX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TJXNeutralLow
01

Why it matters

The disclosed sale provides a datapoint on insider behavior but does not include any new company-specific business, guidance, or regulatory development.

02

Market read

Traders may monitor insider activity for sentiment, but the filing alone is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

The article does not state tax/financing motives, and it notes no 10b5-1 plan, which can increase interpretive noise without adding fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-10; sale executed 2026-06-09

Background

The article is an SEC EDGAR Form 4 disclosure of an insider transaction by TJX executive chairman Carol Meyrowitz.

Company-level read

Ticker impact

$TJXNeutralMedium confidence
Context

SEC Form 4 shows executive chairman Carol Meyrowitz sold 55,624 TJX shares for about $9.1M on 2026-06-09.

Expected impact

Likely limited, short-lived impact; any effect would be sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is primary-source and company-specific, but it is an insider sale (not a buy), with no accompanying operational/regulatory catalyst described.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine liquidity/portfolio rebalancing and may not reflect a bearish view on TJX fundamentals.

Key entities

  • TJX COMPANIES INC /DE/

    Company whose shares were sold by an executive chairman via an SEC Form 4 open-market sale.

  • MEYROWITZ CAROL

    Executive Chairman and officer/director who sold 55,624 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TJXHighAI 8/10

TJX Raises Fiscal 2027 Outlook as Q2 Results Show Broad-Based Growth

TJX raised its fiscal 2027 profit and earnings outlook after Q2 results exceeded expectations. Adjusted earnings rose 11% to $1.22 per share, and net sales increased 5% to $15.18 billion. Management also increased its long-term store target. Marmaxx, the largest division, showed the weakest growth at 1%, while other divisions performed better.

$TJXMedAI 8/10

Should Investors Buy TJX as Growth Improves but Valuation Stays Rich?

TJX reported strong Q2 results with rising sales and raised its fiscal 2027 earnings guidance to $5.15-$5.20 per share. The company plans to expand its store count to 7,500 and accelerate growth. However, its valuation remains high, with a forward P/S ratio of 2.06, above industry and historical averages. TJX's cash flow and shareholder returns are robust, but execution and cost pressures remain risks.

$TJXHighAI 8/10

TJX Falls 17.4% in the Past Month as Strong Results Meet Key Risks

TJX Companies Inc. (TJX) shares fell 17.4% in the past month despite beating Q2 earnings estimates and raising its full-year outlook. Q2 sales rose 5% to $15.18B, but Marmaxx's 1% comparable sales growth missed expectations. Management cited merchandise mix issues. TJX faces cost pressures from wages, fuel, and currency fluctuations, with Q3 gross margin expected to decline. The stock's valuation remains high, trading at a premium to its sub-industry and historical median.

$TJXMed

Tjx stock hits 52-week low at 125.5 USD

TJX Companies' stock hit a 52-week low of $125.49, down 26% from its high. Despite a 1-year decline of 9.66% and YTD losses of 17%, InvestingPro suggests it may be undervalued. Q2 fiscal 2027 results beat estimates, with $15.2B revenue and $1.22 EPS. Analysts have mixed views, with Jefferies downgrading to Hold, Bernstein maintaining Outperform, and UBS raising its target to $198.